ストックスクリーナーアプリを入手
13.53
4.00%
0.52
アフターアワーズ：
13.53
前日終値:
$13.01
開ける：
$12.79
24時間の取引高:
2.45M
Relative Volume:
1.01
時価総額：
$1.54B
収益：
$59.61M
当期純損益:
$-262.14M
株価収益率:
-3.4515
EPS:
-3.92
ネットキャッシュフロー:
$-247.49M
1週間 パフォーマンス:
+4.56%
1か月 パフォーマンス:
-20.46%
6か月 パフォーマンス:
+62.82%
1年 パフォーマンス:
+48.68%
1日の値動き範囲:
$12.79
$14.01
1週間の範囲:
$12.51
$14.01
52週間の値動き範囲:
$6.99
$17.75
Arcutis Biotherapeutics Inc Stock (ARQT) Company Profile
名前
Arcutis Biotherapeutics Inc
セクター
電話
805-418-5006
住所
3027 TOWNSGATE ROAD, WESTLAKE VILLAGE, CA
ARQT を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ARQT
Arcutis Biotherapeutics Inc
|
13.53 | 1.54B | 59.61M | -262.14M | -247.49M | -3.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.52 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.49 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
595.70 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
232.75 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
229.22 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Arcutis Biotherapeutics Inc Stock (ARQT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-12-30 | 開始されました | H.C. Wainwright | Buy |
| 2024-08-28 | 開始されました | Jefferies | Buy |
| 2024-01-03 | アップグレード | Mizuho | Neutral → Buy |
| 2023-10-26 | ダウングレード | Mizuho | Buy → Neutral |
| 2023-10-13 | ダウングレード | Goldman | Buy → Neutral |
| 2022-09-07 | 開始されました | Needham | Buy |
| 2022-03-17 | 開始されました | Goldman | Buy |
| 2021-06-30 | 開始されました | Mizuho | Buy |
| 2021-05-27 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2020-11-09 | アップグレード | Goldman | Neutral → Buy |
| 2020-10-08 | 開始されました | Truist | Buy |
| 2020-02-25 | 開始されました | Cantor Fitzgerald | Overweight |
| 2020-02-25 | 開始されました | Cowen | Outperform |
| 2020-02-25 | 開始されました | Goldman | Neutral |
| 2020-02-25 | 開始されました | Guggenheim | Buy |
すべてを表示
Arcutis Biotherapeutics Inc (ARQT) 最新ニュース
Learn to Evaluate (ARQT) using the Charts - news.stocktradersdaily.com
Arcutis Opportunity To Capitalize On Leadership, Pipeline, And Commercial Assets - Seeking Alpha
Atopic Dermatitis Drugs Market Forecast 2025-2034 | Rising Drug Approvals and Clinical Trial Successes Propel Revenue Growth, Making Atopic Dermatitis a High-Growth Market - GlobeNewswire Inc.
Arcutis to Report First Quarter 2025 Financial Results and Host Conference Call on May 6, 2025 - The Manila Times
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT): Is Breakeven Near? - simplywall.st
Arcutis Biotherapeutics Appoints New Chief Financial Officer - MSN
Arcutis Announces Chief Financial Officer Transition | ARQT Stoc - GuruFocus
Arcutis Biotherapeutics (ARQT) Announces CFO Transition - GuruFocus
Arcutis Biotherapeutics (ARQT) Announces Transition in CFO Role - GuruFocus
Arcutis Names New Chief Financial Officer - Contract Pharma
Arcutis Announces Chief Financial Officer Transition - BioSpace
Arcutis CFO David Topper retires, Latha Vairavan steps in By Investing.com - Investing.com Canada
Arcutis Biotherapeutics Names New Chief Financial Officer - marketscreener.com
Arcutis CFO David Topper retires, Latha Vairavan steps in - Investing.com Australia
Psoriasis Pipeline Analysis and Clinical Trials Assessment, - openPR.com
Arcutis Promotes 20-Year Biotech Veteran to CFO Amid Strong ZORYVE Growth - Stock Titan
Arcutis at Needham Conference: Strategic Growth in Dermatology By Investing.com - Investing.com Canada
Arcutis Biotherapeutics: Zoryve's Growth Impresses, But Valuation Is A Concern (Rating Upgrade) - Seeking Alpha
Arcutis Biotherapeutics (ARQT) Moves 10.8% Higher: Will This Strength Last? - MSN
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Arcutis Strengthens Team with Strategic Stock Grants to 5 Key New Hires - Stock Titan
(ARQT) Trading Report - news.stocktradersdaily.com
Arcutis stock holds buy rating, $19 target amid patent case By Investing.com - Investing.com Australia
Arcutis Biotherapeutics director sells $151,236 in stock By Investing.com - Investing.com South Africa
Arcutis Biotherapeutics director sells $151,236 in stock - Investing.com India
Recent Insider Transactions at Arcutis Biotherapeutics - TradingView
Demystifying Arcutis Biotherapeutics: Insights From 9 Analyst Reviews - Benzinga
Arcutis stock holds buy rating, $19 target amid patent case - Investing.com
Why Arcutis Biotherapeutics Inc. (ARQT) Went Up On Wednesday? - Yahoo Finance
Arcutis and Padagis Agree to Stay Patent Lawsuit - The Manila Times
Arcutis Biotherapeutics (ARQT) Shares Rise Amid Patent Lawsuit P - GuruFocus
Arcutis stock rises following litigation stay By Investing.com - Investing.com Canada
Arcutis and Padagis agree to stay patent litigation By Investing.com - Investing.com South Africa
Arcutis And Padagis Agree To Stay Patent Lawsuit - MarketScreener
Arcutis stock gains after pausing patent suit (ARQT:NASDAQ) - Seeking Alpha
Arcutis rises after halting patent dispute with Padagis - TradingView
Arcutis Agrees to Stay Patent Lawsuit Against Padagis - MarketScreener
Arcutis and Padagis agree to stay patent litigation - Investing.com
Strategic Win: Arcutis Secures Extended Patent Protection for ZORYVE Until 2037 - Stock Titan
Arcutis: An Agent of Patient-Centric Transformation - Technology Magazine
Seborrhoeic Dermatitis Market Growth to Accelerate in Forecast - openPR.com
How Much Upside is Left in Arcutis Biotherapeutics (ARQT)? Wall Street Analysts Think 25.85% - MSN
Why IBD 50's Arcutis Is Outplaying The Biotech Tape And Just Reentered Its Buy Zone - MSN
Arcutis Biotherapeutics Inc (ARQT) 財務データ
収益
当期純利益
現金流量
EPS
0.15%
4.32%
大文字化:
|
ボリューム (24 時間):